Bridging Epigenetics and Development to Reveal Novel Therapeutic Targets in Pediatric Cancers

Genomic instability is a well-studied driver for many adult cancers, however recent data have clearly identified subsets of pediatric cancers that have few, if any, genetic lesions. This observation has led us, and others, to investigate non-genetic mechanisms that contribute to cancer progression such as epigenetics. Integrative epigenetic analysis revealed oncogenes and tumor suppressors that are deregulated in retinoblastoma and, more recently, in rhabdomyosarcoma. These data shed light on promising novel therapeutics that was otherwise not considered before for these diseases.

• Livestreaming is available for this Grand Rounds through UAHS Biocommunications.
• Light refreshments will be provided.

Outcome Objectives: 

1. Describe recent progress in the research, diagnosis and treatment of genetic disorders
2. Discuss how variation in the human genome influences health and disease
3. Integrate advances in genetic diagnosis and treatment into the day-to-day practices of research and clinical care.

Accreditation Statement:

The University of Arizona College of Medicine - Tucson is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

The University of Arizona College of Medicine - Tucson designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit(s)^TM.  Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Disclosure Statement(s):

All Faculty, CME Planning Committee Members, and the CME Office Reviewers have disclosed that they have no financial relationships with commercial interests that would constitute a conflict of interest concerning this CME activity.